CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Elmar Nurmemmedov, Ph.D.
Assistant Professor and Director of Drug Discovery
Saint John's Cancer Institute
Saint John's Health Center
Santa Monica, Calif.
In Person Seminar: CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Date: Oct. 29, 2021
Time: 11:00 a.m. - 12:00 p.m.
Archived video
About this Seminar
Glioblastoma is a highly aggressive form of brain cancer. Therapeutic intervention of glioblastoma through epigenetic shapers such as CHD4 is established as a promising avenue for clinical impact. Despite the accumulating evidence suggesting the importance of CHD4 in glioblastoma, little effort has been done to develop specific CHD4 inhibitors.
In his lab, Dr. Nurmemmedov and his team have taken a unique approach to targeting CHD4 in glioblastoma. They have designed a two-arm therapeutic discovery approach that combined tiling CRISPR screen together with rational chemical biology. The CRISPR study identified the therapeutically vulnerable sites of the CHD4 protein. On the other hand, using rigorous biology and chemistry, the team has identified several novel inhibitors of CHD4. They hypothesize that a selective CHD4 inhibitor would specifically impair tumor growth while sparing healthy cells and could potentially have a therapeutic application for glioblastoma. These inhibitors demonstrate selectivity, target engagement, and unique mechanism of action. Once fully investigated, these molecules could be used to prevent therapy resistance in glioblastomas, with potential translation to the clinic.
You May Also Be Interested In...
-
Home Item
The New Era in Alzheimer's Diagnosis and Treatment , homeMay 14, 2026, 5:30 p.m. (Reception at 5 p.m.) | John C. Morris, M.D., Friedman Distinguished Professor of Neurology, Director, Knight Alzheimer Disease Research Center, Washington University School of Medicine | Maury Strauss Distinguished Public Lecture
-
Home Item
Spatial Disorder in the Aging Brain , homeMay 15, 2026, 11 a.m. | Paul Laurienti, M.D., Ph.D., Professor, Department of Radiology, Wake Forest University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
Unraveling Mechanisms of BCAA Compartmentalization and Crosstalk in Cardiometabolic Disease , homeMay 29, 2026, 11:00 a.m. | Phillip J. White, Ph.D., Associate Professor of Medicine, Division of Endocrinology, Metabolism, & Nutrition, Duke Molecular Physiology Institute, Duke University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Exercise Medicine Research
-
Home Item
The Symphonic Biology of Exercise , homeJune 4, 2026, 5:30 p.m. (Reception at 5 p.m.) | R. Sanders Williams, M.D., Professor and Dean Emeritus, School of Medicine, Senior Advisor for Science & Technology, Duke University | Maury Strauss Distinguished Public Lecture